Precision BioSciences Advances PBGENE-HBV to Phase 2
Precision BioSciences reported Phase 1 findings supporting the program’s advancement and received clearance to dose additional patients in its DMD trial.
Precision BioSciences reported Phase 1 findings supporting the program’s advancement and received clearance to dose additional patients in its DMD trial.